Citations

Mayo Clinic

Showing 10 of 108599 citations.

P352 EXPLORATORY ANALYSES FROM APOLLO–B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
Kale, Pratibha , Fontana, Marianna , Grogan, Martha , Palacek, T., Hung, R, Puolsen, S, Perfetto, Federico , Yu, W, Sarswat, N., Yureneva, Elena, Jay, Patrick Y. , Cappelli, Francesco , Kale, P, Maurer, Matthew J. , Fontana, Marianna , Fernandes, Fábio Danziato , Taylor, Mark , Hung, R, González-Duarte, Alejandra , Donal, Erwan , Tsujita, Kenichi , White, M, Vest, J, Gillmore, Julian D.

European Heart Journal Supplements | May 18, 2023 | Volume: 25 | Issue: Supplement_D | Pages: D181-D182

10.1093/eurheartjsupp/suad111.425 Get It

Abstract Introduction Transthyretin–mediated (ATTR) amyloidosis is a progressive and fatal disease. Patients with hereditary or wild–type ATTR amyloidosis frequently develop cardiomyopathy (CM). Patisiran, an IV RNAi therapeutic that inhibits synthesis of wt and variant TTR, is approved for the treatment of hATTR amyloidosis with polyneuropathy. Methods In APOLLO–B, patients were 18–85 yrs old with evidence of cardiac amyloidosis by echocardiography, ATTR amyloid deposition on tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with CM, and had prior hospitalization for heart failure (HF) due to ATTR amyloidosis or clinical evidence of HF. Patients were randomized 1:1 to patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. The primary endpoint was change from baseline in 6–MWT at Month 12 (M12) with patisiran vs placebo. Exploratory parameters at M12 included changes in cardiac biomarkers, echocardiography and Tc scintigraphy. Results APOLLO–B enrolled 360 patients (patisiran, n=181; placebo, n=179): median age, 76.0 yrs; male, 89%; wtATTR, 80%; on tafamidis at baseline, 25%. Patisiran showed a significant benefit compared with placebo in 6–MWT (median [95% CI] change from baseline: patisiran, –8.15 [–16.42, 1.50]; placebo, –21.35 [–34.05, –7.52]; HL estimate of median difference: 14.69 [0.69, 28.69]; p=0.0162). Patisiran demonstrated favorable trends in change from baseline of NT–proBNP (mean fold change ratio [95% CI]: 0.80 [0.73, 0.89]; p=1.825×10–5) and troponin I (mean fold change ratio [95% CI]: 0.87 [0.80, 0.95]; p=0.0011) at M12 vs placebo. Patisiran also demonstrated a trend towards benefit in change from baseline of most evaluated echocardiographic parameters at M12 vs placebo. Patisiran–treated patients evaluable for scintigraphy (n=37) experienced a reduction (37.8%) or no change (62.2%) in Perugini grade at M12 compared with baseline. Among placebo patients (n=28) at M12, none experienced a reduction from baseline in Perugini grade, and 1 (3.6%) increased in grade. Patisiran demonstrated an acceptable safety profile; AEs were mostly mild or moderate in severity, and there were no cardiac safety concerns. Conclusions Exploratory analyses after 12 months provide further evidence for the potential benefit of patisiran treatment on cardiac biomarkers and manifestations of cardiac amyloid involvement in patients with ATTR amyloidosis. The long–term impact of patisiran will be assessed in the ongoing APOLLO–B open–label extension.
75. Evaluating the Long-term Outcomes Associated with the Use of Fresh Frozen Allograft Cartilage in Cosmetic and Reconstructive Rhinoplasty Procedures: A Prospective Controlled Clinical Trial
Wan, Rou , Weissman, Joshua P. , Joshi, Chitang , Putnam, G.E., Williams, Tokoya, Putnam, Genevieve, Galiano, Robert D.

Plastic and Reconstructive Surgery - Global Open | May 18, 2023 | Volume: 11 | Issue: 5S | Pages: 47-47

10.1097/01.gox.0000937892.22859.d5 Get It

Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV
Zeuli, John D. , Wright, Jessica , Kasten, Mary J. , Ragan, Ashley Kate, Rizza, Stacey A. , Temesgen, Zelalem , Vergidis, Paschalis , Wilson, John , Vergidis, Paschalis , Wright, Jessica A , Rivera, Christina G. , Mahmood, Maryam , Cummins, Nathan W.

AIDS | May 18, 2023 | Volume: 37 | Issue: 10 | Pages: 1525-1533

10.1097/qad.0000000000003598 | PMID 37199600 Get It

Objective: Our study aimed to assess the impact of pharmacogenomic panel testing in people with HIV (PWH). Design: Prospective, observational intervention assessment Methods: One hundred PWH were provided a comprehensive pharmacogenomic panel during routine care visits within the HIV specialty clinic of a large academic medical center. The panel determined the presence of specific genetic variants that could predict response or toxicity to commonly prescribed antiretroviral therapy (ART) and non-ART medications. An HIV specialty pharmacist reviewed the results with participants and the care team. The pharmacist (1) recommended clinically actionable interventions based on the participants’ current drug therapy, (2) assessed for genetic explanations for prior medication failures, adverse effects, or intolerances, and (3) advised on potential future clinically actionable care interventions based on individual genetic phenotypes. Results: Ninety-six participants (median age 53 years, 74% white, 84% men, 89% viral load <50 copies/ml) completed panel testing, yielding 682 clinically relevant pharmacogenomic results (133 major, 549 mild–moderate). Ninety participants (89 on ART) completed follow-up visits with 65 (72%) receiving clinical recommendations based on current medication profiles. Of the 105 clinical recommendations, 70% advised additional monitoring for efficacy or toxicity, and 10% advised alteration of drug therapy. Panel results offered explanation for prior ART inefficacy in one participant and ART intolerance in 29%. Genetic explanation for non-ART toxicity was seen in 21% of participants, with genetic contributors to inefficacy of non-ART therapy identified in 39% of participants. Conclusion: Preliminary data in a small cohort of PWH demonstrates benefit of routine pharmacogenomic panel testing.
Low Tidal Volume Strategy: What Else?*
Puentes, G.A. Cortes, Bauer, Philippe R.

Critical Care Medicine | May 18, 2023 | Volume: 51 | Issue: 6 | Pages: 838-841

10.1097/ccm.0000000000005868 | PMID 37199554 Get It

Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants
Chen, Xuan , Meyer, Margaret, Kemppainen, Jennifer L., Horibe, Masayasu, Chandra, Shruti , Majumder, Shounak, Petersen, Gloria M. , Majumder, Shounak , Rabe, Kari G. , Majumder, Shounak , Meyer, Margaret A., Horibe, Masayasu

JAMA Oncology | May 18, 2023 | Volume: 9 | Issue: 7 | Pages: 955

10.1001/jamaoncol.2023.0806 | PMID 37200008 Get It

ImportanceIncreased cancer risk in first-degree relatives of probands with pancreatic ductal adenocarcinoma (PDAC probands) who carry pathogenic or likely pathogenic germline variants (PGVs) in cancer syndrome–associated genes encourages cascade genetic testing. To date, unbiased risk estimates for the development of cancers on a gene-specific basis have not been assessed.ObjectiveTo quantify the risk of development of PDAC and extra-PDAC among first-degree relatives of PDAC probands who carry a PGV in 1 of 9 cancer syndrome–associated genes—ATM, BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2, and CDKN2A.Design, Setting, and ParticipantsThis case series focused on first-degree relatives of PDAC probands carrying PGVs in specific cancer syndrome–associated genes. The cohort comprised clinic-ascertained patients enrolled in the Mayo Clinic Biospecimen Resource for Pancreas Research registry with germline genetic testing. In total, 234 PDAC probands carrying PGVs were drawn from the prospective research registry of 4562 participants who had undergone genetic testing of cancer syndrome–associated genes. Demographic and cancer-related family histories were obtained by questionnaire. The data were collected from October 1, 2000, to December 31, 2021.Main Outcomes and MeasuresFor the PDAC probands, the genetic test results of the presence of PGVs in 9 cancer syndrome–associated genes were obtained by clinical testing. Cancers (ovary, breast, uterus or endometrial, colon, malignant melanoma, and pancreas) among first-degree relatives were reported by the probands. Standardized incidence ratios (SIRs) were used to estimate cancer risks among first-degree relatives of PDAC probands carrying a PGV.ResultsIn total, 1670 first-degree relatives (mean [SD] age, 58.1 [17.8] years; 853 male [51.1%]) of 234 PDAC probands (mean [SD] age, 62.5 [10.1] years; 124 male [53.0%]; 219 [94.4%] White; 225 [98.7%] non-Hispanic or non-Latino]) were included in the study. There was a significantly increased risk of ovarian cancer in female first-degree relatives of probands who had variants in BRCA1 (SIR, 9.49; 95% CI, 3.06-22.14) and BRCA2 (SIR, 3.72; 95% CI, 1.36-8.11). Breast cancer risks were higher with BRCA2 variants (SIR, 2.62; 95% CI, 1.89-3.54). The risks of uterine or endometrial cancer (SIR, 6.53; 95% CI, 2.81-12.86) and colon cancer (SIR, 5.83; 95% CI, 3.70-8.75) were increased in first-degree relatives of probands who carried Lynch syndrome mismatch repair variants. Risk of PDAC was also increased for variants in ATM (SIR, 4.53; 95% CI, 2.69-7.16), BRCA2 (SIR, 3.45; 95% CI, 1.72-6.17), CDKN2A (SIR, 7.38; 95% CI, 3.18-14.54), and PALB2 (SIR, 5.39; 95% CI, 1.45-13.79). Melanoma risk was elevated for first-degree relatives of probands with CDKN2A variants (SIR, 7.47; 95% CI, 3.97-12.77).Conclusions and RelevanceIn this case series, the presence of PGVs in 9 cancer syndrome–associated genes in PDAC probands was found to be associated with increased risk of 6 types of cancers in first-degree relatives. These gene-specific PDAC and extra-PDAC cancer risks may provide justification for clinicians to counsel first-degree relatives about the relevance and importance of genetic cascade testing, with the goal of higher uptake of testing.
Bibliometric Analysis of the Top 50 Most Cited Studies on Achilles Tendon Pathology
Hawkins, Ryan J., Makovicka, Justin L. , Haglin, Jack M. , Brinkman, Joseph C. , Moore, M. Lane , Pollock, Jordan Riley , Patel, Karan A.

Orthopaedic Journal of Sports Medicine | May 18, 2023 | Volume: 11 | Issue: 5 | Pages: No page available

10.1177/23259671221134117 | PMID 37223074 Get It

Background: The development of Achilles tendon treatment modalities has been rapid, and it is increasingly difficult for clinicians to stay up to date with the most influential studies in this field. In order to fully understand the current state of the literature regarding Achilles tendon injury, it is invaluable to be familiar with the foundational articles and studies upon which the field is built. Purpose: To objectively determine the 50 most frequently cited studies in Achilles tendon pathology and to conduct a bibliometric analysis. Study Design: Cross-sectional study. Methods: The Clarivate Analytics Web of Knowledge database was used to gather data and metrics of Achilles tendon research. The 50 most cited articles were selected for analysis from an initial 17,244 identified articles. The information extracted for each article included author name, publication year, country of origin, journal name, study type, and level of evidence. Results: For these 50 studies, the total number of citations was calculated to be 13,159, with a mean of 263.2 citations per paper. The most cited article collected 657 citations. The publication dates of the 50 studies included in this analysis spanned 41 years (1972-2013). The largest number of articles were published by Swedish authors (n = 14); however, many other countries were represented, including Canada and Finland (n = 6 articles each). The most prevalent study designs were cohort studies (n = 13) with level 4 evidence studies being the most common (n = 14). Conclusion: Among the 50 most influential articles in Achilles tendon pathology, the study designs most commonly used were cohort studies and review articles. Sweden was the country of origin for the most studies included on this list, which reflects this country’s interest and commitment to researching Achilles tendon injuries and treatments.
Payment and Coverage Parity for Virtual Care and In-Person Care: How Do We Get There?
Khera, Nandita , Knoedler, Meghan , Meier, Sarah , TerKonda, Sarvam P. , Williams, Ryan, Wittich, Christopher M. , Coffey, Jordan , Demaerschalk, Bart M. , Meier, Sarah K, TerKonda, Sarvam , Williams, Ryan D, Coffey, Jordan D, Demaerschalk, Bart M , Coffey, Jordan D , Williams, Ryan D.

Telemedicine Reports | May 18, 2023 | Volume: 4 | Issue: 1 | Pages: 100-108

10.1089/tmr.2023.0014 | PMID 37283856 Get It

Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent
Chowdhury, Uttio Roy, Chowdhury, Uttio Roy, Pervan-Steel, Cynthia L., Pervan-Steel, Cynthia L., Sheeler, Ryan, Sookdeo, H, Rogers, Brian, Casale, Ralph, Dosa, Peter I. , Htoo, Thurein, Wirostko, Barbara, Fautsch, Michael P. , Roy Chowdhury, Uttio, Fautsch, Michael P , Chowdhury, Uttio Roy, Pervan-Steel, Cynthia L., Pervan-Steel, Cynthia L., Rogers, Brian

Journal of Ocular Pharmacology and Therapeutics | May 18, 2023 | Volume: 39 | Issue: 5 | Pages: 332-346

10.1089/jop.2022.0184 | PMID 37200453 Get It

Successful Treatment of Achalasia With Endoscopic Ultrasound–Guided Botulinum Injection in Setting of Esophageal Varices
Chase, R. Christopher , Gómez, Victoria , Pang, Maoyin , Chase, R Christopher , Liu, Yang

ACG Case Reports Journal | May 18, 2023 | Volume: 10 | Issue: 5 | Pages: e01055

10.14309/crj.0000000000001055 Get It

ABSTRACT Achalasia in a patient with liver cirrhosis decompensated by esophageal varices is an extremely rare presentation with complex management implications. We describe a case of achalasia and malnutrition in a male patient with esophageal varices treated by endoscopic ultrasound–guided botulinum toxin injection. After treatment, the patient's dysphagia dramatically improved, and his weight loss stabilized, which allowed an important window to remove the barrier of nutritional status for transplant candidacy. Endoscopic ultrasound–guided botulinum toxin injection to avoid varices is potentially a safer method for delivering botulinum toxin injection to the lower esophageal sphincter in a patient with esophageal varices.
Biosensors: An Upcoming Wave of Innovation
Skladman, Rachel, Kinney, Brian M. , Jeffers, Lynn , Gurtner, Geoff, Nachbar, James, TerKonda, Sarvam P. , Reddy, Sashank , Sacks, Justin M.

Plastic & Reconstructive Surgery | May 18, 2023 | Volume: 153 | Issue: 4 | Pages: 967-975

10.1097/prs.0000000000010607 | PMID 37199437 Get It

Summary: A biosensor uses a biological molecule to measure a chemical reaction. Wearable biosensors that attach to the body externally, including tooth enamel biosensors, contact lens biosensors, sweat biosensors, and skin tattoo biosensors, are in development. Nanoparticle-based biosensors are being developed to allow for the early detection of cancerous biomarkers. Applications relevant to plastic surgery include the development of biosensors that can detect metastatic breast cancer cells, bioimpedance spectroscopy, and intraoperative point-of-care diagnostics.